mebeverine has been researched along with Colitis, Mucous in 29 studies
mebeverine: RN given refers to parent cpd; structure
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to examine whether pentoxifylline, a competitive nonselective phosphodiesterase inhibitor, is useful in alleviating abdominal pain in IBS patients treated with mebeverine." | 9.51 | Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine. ( Abd-Elsalam, SM; Bahaa, MM; El-Haggar, SM; Hegazy, SK, 2022) |
| "CBT in addition to mebeverine seems to have reasonable cost-effectiveness in the short-term treatment of irritable bowel syndrome, but not beyond 3 months." | 9.13 | Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome. ( Chalder, T; Darnley, S; Jones, R; Kennedy, T; Knapp, M; McCrone, P; Seed, P, 2008) |
| "We evaluated the efficacy and tolerability of mebeverine, a musculotropic antispasmodic agent, in irritable bowel syndrome (IBS) and compared its usual dosages by meta-analysis." | 8.86 | A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. ( Abdollahi, M; Darvish-Damavandi, M; Nikfar, S, 2010) |
| " The aim of this study was to examine whether pentoxifylline, a competitive nonselective phosphodiesterase inhibitor, is useful in alleviating abdominal pain in IBS patients treated with mebeverine." | 5.51 | Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine. ( Abd-Elsalam, SM; Bahaa, MM; El-Haggar, SM; Hegazy, SK, 2022) |
| "To examine predictors of treatment outcome in IBS-patients who participated in a randomized controlled trial in primary care, where 149 irritable bowel syndrome (IBS) patients were randomized to mebeverine hydrochloride (n=77) or mebeverine+cognitive behavior therapy (CBT) (n=72)." | 5.14 | Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care. ( Chalder, T; Darnley, S; Jones, R; Kennedy, T; Reme, SE, 2010) |
| "CBT in addition to mebeverine seems to have reasonable cost-effectiveness in the short-term treatment of irritable bowel syndrome, but not beyond 3 months." | 5.13 | Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome. ( Chalder, T; Darnley, S; Jones, R; Kennedy, T; Knapp, M; McCrone, P; Seed, P, 2008) |
| "149 patients with moderate or severe irritable bowel syndrome resistant to the antispasmodic mebeverine." | 5.11 | Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. ( Chalder, T; Darnley, S; Jones, R; Kennedy, T; Seed, P; Wessely, S, 2005) |
| "We evaluated the efficacy and tolerability of mebeverine, a musculotropic antispasmodic agent, in irritable bowel syndrome (IBS) and compared its usual dosages by meta-analysis." | 4.86 | A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. ( Abdollahi, M; Darvish-Damavandi, M; Nikfar, S, 2010) |
| " We performed an in-depth case study on mebeverine, a drug prescribed to patients with irritable bowel syndrome, to explore this hypothesis." | 3.74 | Health technology assessment and ill-structured problems: a case study concerning the drug mebeverine. ( Grin, J; Moret-Hartman, M; van der Wilt, GJ, 2007) |
| "Patients identified at community pharmacies, using mebeverine as a proxy for IBS, were administered a questionnaire regarding (1) the Rome II criteria for IBS, (2) predominant type of stool during complaints, (3) severity of symptoms (abdominal pain and discomfort), (4) generic and disease-specific quality of life, (5) current health status (utilities), and (6) loss of productivity." | 3.73 | Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. ( Goettsch, WG; Herings, RM; Smout, AJ; ten Berg, MJ; van den Boom, G, 2006) |
| "Mebeverine is a musculotropic agent that potently blocks intestinal peristalsis." | 2.50 | Role of antispasmodics in the treatment of irritable bowel syndrome. ( Annaházi, A; Róka, R; Rosztóczy, A; Wittmann, T, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (41.38) | 29.6817 |
| 2010's | 16 (55.17) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| El-Haggar, SM | 1 |
| Hegazy, SK | 1 |
| Abd-Elsalam, SM | 1 |
| Bahaa, MM | 1 |
| Nguyen, TT | 1 |
| Dau, DT | 1 |
| Nguyen, DC | 1 |
| Nguyen, HT | 1 |
| Ngo, PT | 1 |
| Nguyen, TQ | 1 |
| Han, B | 1 |
| Hoang, BX | 1 |
| Everitt, H | 2 |
| Moss-Morris, R | 2 |
| Sibelli, A | 2 |
| Tapp, L | 2 |
| Coleman, N | 1 |
| Yardley, L | 2 |
| Smith, P | 1 |
| Little, P | 1 |
| Sahib, AS | 1 |
| Tonkin-Crine, S | 1 |
| Bishop, FL | 1 |
| Ellis, M | 1 |
| Rahman, MZ | 1 |
| Ahmed, DS | 1 |
| Mahmuduzzaman, M | 1 |
| Rahman, MA | 1 |
| Chowdhury, MS | 1 |
| Barua, R | 1 |
| Ishaque, SM | 1 |
| Annaházi, A | 1 |
| Róka, R | 1 |
| Rosztóczy, A | 1 |
| Wittmann, T | 1 |
| Hou, X | 1 |
| Chen, S | 1 |
| Zhang, Y | 1 |
| Sha, W | 1 |
| Yu, X | 1 |
| Elsawah, H | 1 |
| Afifi, AF | 1 |
| El-Khayat, HR | 1 |
| Nouh, A | 1 |
| Hassan, MF | 1 |
| Fatah, AA | 1 |
| Rucker Joerg, I | 1 |
| Sánchez Núñez, JM | 1 |
| Osthoff Rueda, R | 1 |
| Jurkowska, G | 1 |
| Walczak, M | 1 |
| Malecka-Panas, E | 1 |
| Linke, K | 1 |
| Hartleb, M | 1 |
| Janssen-van Solingen, G | 1 |
| Dumitrascu, DL | 1 |
| Chira, A | 1 |
| Bataga, S | 1 |
| Diculescu, M | 1 |
| Drug, V | 1 |
| Gheorghe, C | 1 |
| Goldis, A | 1 |
| Nedelcu, L | 1 |
| Porr, PJ | 1 |
| Sporea, I | 1 |
| Dance, A | 1 |
| Heldwein, W | 1 |
| Eisenlohr, H | 1 |
| Kapoor, S | 1 |
| Darvish-Damavandi, M | 1 |
| Nikfar, S | 1 |
| Abdollahi, M | 1 |
| Reme, SE | 2 |
| Kennedy, T | 4 |
| Jones, R | 4 |
| Darnley, S | 5 |
| Chalder, T | 5 |
| Everitt, HA | 1 |
| Moss-Morris, RE | 1 |
| Coleman, NS | 1 |
| Smith, PW | 1 |
| Little, PS | 1 |
| Stahl, D | 1 |
| Mönnikes, H | 1 |
| Lee, KJ | 1 |
| Kim, NY | 1 |
| Kwon, JK | 1 |
| Huh, KC | 1 |
| Lee, OY | 1 |
| Lee, JS | 1 |
| Choi, SC | 1 |
| Sohn, CI | 1 |
| Myung, SJ | 1 |
| Park, HJ | 1 |
| Choi, MK | 1 |
| Bak, YT | 1 |
| Rhee, PL | 1 |
| Clavé, P | 1 |
| Goettsch, WG | 2 |
| van den Boom, G | 2 |
| Breekveldt-Postma, NS | 1 |
| Smout, AJ | 2 |
| Herings, RM | 2 |
| Seed, P | 2 |
| Wessely, S | 2 |
| Enck, P | 1 |
| Klosterhalfen, S | 1 |
| Kruis, W | 1 |
| Müller-Lissner, S | 1 |
| ten Berg, MJ | 1 |
| Kennedy, TM | 1 |
| McCrone, P | 2 |
| Knapp, M | 2 |
| Jones, RH | 1 |
| Mearin, F | 1 |
| Moret-Hartman, M | 1 |
| van der Wilt, GJ | 1 |
| Grin, J | 1 |
| Andresen, V | 1 |
| Montori, VM | 1 |
| Keller, J | 1 |
| West, CP | 1 |
| Layer, P | 1 |
| Camilleri, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Management of Irritable Bowel Syndrome in Primary Care: Feasibility Randomised Controlled Trial of Mebeverine, Methylcellulose, Placebo and a Patient Self-management Cognitive Behavioural Therapy Website. (MIBS Trial)[NCT00934973] | Phase 4 | 135 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Sexual Dysfunction, Quality of Life and Visceral Hyperalgesia in Women With Irritable Bowel Syndrome[NCT04716738] | 20 participants (Anticipated) | Observational [Patient Registry] | 2023-02-01 | Not yet recruiting | |||
| Persistent Physical Symptoms Reduction Intervention: a Systems Change and Evaluation (PRINCE) - Integrated GP Care for Persistent Physical Symptoms: a Feasibility & Cluster Randomised Controlled Trial[NCT02444520] | 161 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for mebeverine and Colitis, Mucous
| Article | Year |
|---|---|
Role of antispasmodics in the treatment of irritable bowel syndrome.
Topics: Abdominal Pain; Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Disease Models, Animal | 2014 |
The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence.
Topics: Drug Therapy, Combination; Evidence-Based Medicine; Gastroenterology; Gastrointestinal Agents; Human | 2014 |
[Irritable bowel syndrome-an unbeloved problem].
Topics: Antidepressive Agents; Antidiarrheals; Cholinergic Antagonists; Colonoscopy; Diagnosis, Differential | 2008 |
A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome.
Topics: Anticonvulsants; Databases, Factual; Female; Humans; Irritable Bowel Syndrome; Male; Parasympatholyt | 2010 |
Quality of life in patients with irritable bowel syndrome.
Topics: Aged; Carbolines; Constipation; Diarrhea; Female; Gastrointestinal Agents; Health Status; Humans; Ir | 2011 |
[Drug treatment of irritable bowel syndrome: an unmet need].
Topics: Abdominal Pain; Analgesics; Antidepressive Agents, Tricyclic; Antidiarrheals; Carbolines; Controlled | 2007 |
Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Carbazoles; Carbolines; Constipation; Diarrhea; Dose-Response Relationship, Dr | 2008 |
12 trials available for mebeverine and Colitis, Mucous
| Article | Year |
|---|---|
Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine.
Topics: Abdominal Pain; Adult; Anti-Inflammatory Agents; Drug Therapy, Combination; Female; Humans; Irritabl | 2022 |
Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website.
Topics: Adolescent; Adult; Cognitive Behavioral Therapy; Follow-Up Studies; Humans; Internet; Irritable Bowe | 2013 |
Treatment of irritable bowel syndrome using a selected herbal combination of Iraqi folk medicines.
Topics: Adult; Cyperus; Female; Gastrointestinal Agents; Humans; Iraq; Irritable Bowel Syndrome; Male; Medic | 2013 |
Exploring patients' views of a cognitive behavioral therapy-based website for the self-management of irritable bowel syndrome symptoms.
Topics: Adult; Cognitive Behavioral Therapy; Female; Humans; Internet; Irritable Bowel Syndrome; Male; Methy | 2013 |
Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome.
Topics: Adolescent; Adult; Bangladesh; Female; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Pain Mea | 2014 |
Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care.
Topics: Adolescent; Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Irritabl | 2010 |
Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial).
Topics: Adolescent; Adult; Cognitive Behavioral Therapy; Humans; Internet; Irritable Bowel Syndrome; Methylc | 2010 |
Mediators of change in cognitive behaviour therapy and mebeverine for irritable bowel syndrome.
Topics: Adolescent; Adult; Anxiety; Cognitive Behavioral Therapy; Combined Modality Therapy; Humans; Irritab | 2011 |
Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
Topics: Adolescent; Adult; Benzimidazoles; Diarrhea; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Pa | 2011 |
Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial.
Topics: Adolescent; Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Humans; Irritable Bowel | 2005 |
Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial.
Topics: Adolescent; Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Irritabl | 2006 |
Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome.
Topics: Adolescent; Adult; Anticonvulsants; Cognitive Behavioral Therapy; Combined Modality Therapy; Cost of | 2008 |
10 other studies available for mebeverine and Colitis, Mucous
| Article | Year |
|---|---|
Effects of Trang Phuc Linh Plus-Food Supplement on Irritable Bowel Syndrome Induced by Mustard Oil.
Topics: Animals; Colitis; Colon; Dietary Supplements; Drug Combinations; Female; Gastrointestinal Motility; | 2017 |
Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observa
Topics: Adult; Aged; Aged, 80 and over; China; Cohort Studies; Drug Administration Schedule; Egypt; Humans; | 2014 |
Transit time.
Topics: Anti-Bacterial Agents; Biofeedback, Psychology; Carbolines; Colitis; Diet; Dysentery; Dyspepsia; Egy | 2016 |
Psychological associations of irritable bowel syndrome besides panic disorder: an often overlooked reality.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Drug Therapy, Combina | 2009 |
Treatment of IBS-D with 5-HT3 receptor antagonists vs spasmolytic agents: similar therapeutical effects from heterogeneous pharmacological targets.
Topics: Benzimidazoles; Diarrhea; Humans; Irritable Bowel Syndrome; Male; Parasympatholytics; Phenethylamine | 2011 |
Treatment patterns and health care costs of mebeverine-treated IBS patients: a case-control study.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Cathartics; Health Care Costs; Hospitalization; Human | 2004 |
[Determination of placebo effect in irritable bowel syndrome].
Topics: Adult; Analysis of Variance; Data Interpretation, Statistical; Dietary Fiber; Double-Blind Method; F | 2005 |
"My patients are the sickest".
Topics: Humans; Irritable Bowel Syndrome; Parasympatholytics; Patient Acceptance of Health Care; Phenethylam | 2006 |
Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases.
Topics: Abdominal Pain; Chronic Disease; Constipation; Cost of Illness; Diarrhea; Female; Health Status; Hea | 2006 |
Health technology assessment and ill-structured problems: a case study concerning the drug mebeverine.
Topics: Governing Board; Health Policy; Humans; Irritable Bowel Syndrome; Organizational Case Studies; Paras | 2007 |